Grail Trading Halted Ahead of FDA Panel Review of Galleri Cancer Test
ILMN has more than doubled off its 52-week low of $88.
Summary
Grail shares are halted ahead of today's FDA advisory committee meeting on its Galleri multi-cancer blood test. The stock had already surged 34% this week after Monday's briefing documents suggested the FDA is more focused on labeling than on safety or efficacy concerns. An RBC analyst noted the agency appears less worried about the test's fundamentals, which could smooth the path to approval. Illumina spun off Grail but retains a significant stake, so a positive panel vote would directly boost Illumina's valuation. The advisory committee's recommendation is expected after the meeting concludes, and the FDA typically follows its advice.
At the time of this announcement, ILMN was trading at $247.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.4B. The 52-week trading range was $88.00 to $250.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.